Back to today’s briefing

Story perspectives

Breakthrough Phage Therapy Shows Promise for Diabetic Foot Ulcers

3/31/2025

43 8

Summary

Story summary

BiomX's CEO, Jonathan Solomon, unveiled exciting results from the Phase II trial of BX211, a groundbreaking phage therapy targeting diabetic foot osteomyelitis caused by S. aureus. The treatment demonstrated remarkable reductions in ulcer depth and size. Backed by the U.S. Defense Health Agency, this innovation could transform phage therapy and provide new hope against antibiotic resistance for patients globally.

1 of 1

Story summary

BiomX's CEO, Jonathan Solomon, unveiled exciting results from the Phase II trial of BX211, a groundbreaking phage therapy targeting diabetic foot osteomyelitis caused by S. aureus. The treatment demonstrated remarkable reductions in ulcer depth and size. Backed by the U.S. Defense Health Agency, this innovation could transform phage therapy and provide new hope against antibiotic resistance for patients globally.